Paulo S. Pinheiro

University of Miami Miller School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Background This study investigates how demographic and socioeconomic factors influence stage at diagnosis for oral cavity and pharyngeal cancer (OPC) in Florida. Methods We analyzed OPC cases (2005–2021) from the Florida Cancer Data System. Sociodemographic and clinical factors were examined for associations with advanced-stage diagnosis using logistic regression models to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). Separate analyses were also conducted among never smokers to evaluate disparities in non-tobacco-related OPC. Results Among 30,478 patients, most were male (75.1%) and non-Hispanic White (79.7%), with peak prevalence in ages 55–64. Advanced-stage diagnosis was more likely in Black individuals (aOR: 1.55), current smokers (aOR: 1.34), and those in high-poverty areas (aOR: 1.24). Medicaid recipients and uninsured individuals had higher odds (1.83 and 1.77, respectively) than privately insured patients. Salivary gland (aOR: 1.6) and pharyngeal cancers (aOR: 1.7) were more likely to be diagnosed late. Being married was protective (aOR: 0.78). Conclusions Disparities in OPC diagnosis remain. Targeted outreach, improved access, and early screening are critical to reducing late-stage diagnoses.

Year:

2026

Importance: Neuroendocrine tumors (NETs) have traditionally been considered rare (orphan) diseases; however, improvements in diagnostic methods and heightened awareness about NETs may have altered their epidemiologic profile in the U.S. Objective: To evaluate trends in incidence, prevalence, and survival of NETs in the United States from 2000 to 2021 using updated data from the SEER-22 registry. Method: This population-based, retrospective cohort study used the SEER-22 database for incidence, prevalence, and survival analyses. Data included 231,659 patients diagnosed with NETs between 2000 and 2021. Age-adjusted incidence, limited-duration prevalence, 5-year overall survival (OS), and hazard ratios (HRs) for survival by grade, stage, year of diagnosis, race, and primary site were investigated. Results: From 2000 to 2021, NET incidence nearly doubled, from 4.6 to 8.2 per 100,000 persons. The prevalence in 2021 reached 0.064%, with grade 1 tumors showing the steepest increase. Five-year OS was 77.4% overall and highest among localized NETs (82.3%) and grade 1 tumors (80.0%). Multivariable analysis showed improved survival over time (HR for 2015–2021 vs. 2000–2004, 0.92; 95% CI, 0.89–0.95). Black and American Indian/Alaska Native patients had significantly worse outcomes than White patients. Conclusions and Relevance: NETs are no longer orphan diseases based on current U.S. incidence and prevalence trends. With increasing survival and patient numbers, there is an urgent need for expanded multidisciplinary NET care and research efforts focused on survivorship and quality of life.

Year:

2025

Supplementary Table 4 shows the results from the adjusted multivariable logistic regression analyses evaluating for predictors of delays in HCC treatment (≥3 months vs.

Year:

2025

Supplementary figure 1A shows the overall 5-year survival of patients with HCC stratified by age groups. Supplementary figure 1B shows the overall 5-year survival of patients with HCC stratified by sex. Supplementary figure 1C shows the overall 5-year survival of patients with HCC stratified by race/ethnicity. Supplementary figure 1D shows the overall 5-year survival of patients with HCC stratified by geography. Supplementary figure 1E shows the overall 5-year survival of patients with HCC stratified by annual household income.

Year:

2025

Supplementary Table 1 shows the results of adjusted multivariable logistic regression analyses evaluating for predictors of tumor stage at diagnosis among patients with HCC, stratified by race/ethnicity.

Year:

2025

Background: Hepatocellular carcinoma (HCC) disproportionately affects racial/ethnic minorities. We evaluated the impact of income and geography on racial/ethnic disparities across the HCC care cascade in the United States. Methods: Using NCI registry data spanning 2000 to 2020, adults with HCC were evaluated to determine race/ethnicity-specific differences in tumor stage at diagnosis, delays and gaps in treatment, and survival. Adjusted regression models evaluated predictors of HCC outcomes. Results: Among 112,389 adults with HCC, cohort characteristics were as follows: 49.8% non-Hispanic White (NHW), 12.0% African American(AA), 20.5% Hispanic, 16.5% Asian/Pacific Islander, and 1.1% American Indian/Alaska Native. Compared with NHW patients, AA patients had lower odds of localized-stage HCC at diagnosis [adjusted odds ratio (aOR), 0.84], lower odds of HCC treatment receipt (aOR, 0.77), greater odds of treatment delays (aOR, 1.12), and significantly greater risk of death [adjusted hazards ratio (aHR), 1.10]. Compared with NHW patients from large metro areas, AA patients from large metro areas had 8% higher mortality risk (aHR, 1.08), whereas AA patients from small–medium metro areas had 17% higher mortality risk (aHR, 1.17; all P Conclusions: Among a population-based cohort of US adults with HCC, significant race/ethnicity-specific disparities across the HCC care continuum were observed. Lower household income and more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients. Impact: Our study shows that lower income and less urban/more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients with HCC. This contextualizes the complex relationship between sociodemographic factors and HCC outcomes through an intersectional lens.

Year:

2025

We aim to compare cancer mortality rates of USA Colombian migrants (USA Colombians) to Colombians in their country of origin (CO Colombians). Using Colombian national mortality data and data on cancer deaths among Colombians residing in the states of California, Florida, and New York (USA Colombians) for the period 2008-2012, we estimated sex-specific and age-standardized mortality rates (ASMR), expressed per 100,000 persons. For comparisons between the two populations before and after adjustment for educational level, negative binomial regression models were used to compute Mortality Rate Ratios (MRR). CO Colombians had higher cancer mortality rates compared with USA Colombians (male MRR 1.4 [95%CI: 1.2-1.5], female MRR 1.5 [95%CI: 1.3-1.7]). These differences persisted for most cancers even after adjustment for education. CO Colombians had significantly higher mortality from gastric (MRR 2.6 in males and 2.8 in females) and cervical cancer (MRR 5.0) compared with US Colombians. Educational inequalities in cancer mortality were more pronounced among CO Colombians than among USA Colombians. Lower cancer mortality observed among USA Colombians cannot be attributed to differences in education, an indicator of socio-economic status. Rather, it is likely due to better access to preventive and curative healthcare in the USA.

Year:

2024

Background: Previous survival studies on hepatocellular carcinoma (HCC) by etiology are limited to hospital-based series, restricted cohorts, and monolithic etiologic categories. We studied population-based survival by seven mutually exclusive HCC etiologic groups—standalone hepatitis-C virus (HCV), hepatitis-B virus (HBV), alcohol-related liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), and dual etiology HCV–HBV, HCV–ALD, and HBV–ALD—accounting for clinical and sociodemographic characteristics. Methods: All HCC cases diagnosed during 2005 to 2018 from the Florida Cancer Registry were linked for etiology using statewide discharge and viral hepatitis data. We performed a cause-specific survival analysis including Cox regression for the matched 15,616 cases by HCC etiology. Results: The leading etiology was HCV only ( n = 4,983; 31.9%); the leading dual etiology was HCV–ALD ( n = 2,552; 16.3%). The five-year adjusted survival was low—17.6% overall and Conclusions: ALD only and dual etiologies involving ALD show worse prognosis for HCC compared with viral etiology alone. To increase survival, improved screening and treatment are needed for patients with multiple HCC risk factors. Impact: Understanding US disparities in HCC survival by etiology can help guide the identification of etiologically specific biomarkers and potential therapeutic targets and inform public health measures.

Year:

2024

5. Supplementary Table S5 shows age-adjusted 5-year HCC-specific survival by single etiology or select dual etiology groups, a sensitivity analysis for all HCC cases and for complete HCC cases.

Year:

2024

Background: The Hispanic population is the second largest racial/ethnic group in the United States, consisting of multiple distinct ethnicities. Ethnicity-specific variations in cancer mortality may be attributed to countries of birth, so we aimed to understand differences in cancer mortality among disaggregated Hispanics by nativity (native- or foreign-born vs. US-born) over 15 years. Methods: A total of 228,197 Hispanic decedents (Mexican, Puerto Rican, Cuban, and Central or South American) with cancer-related deaths from US death certificates (2003–2017) were analyzed. Seven cancers that contribute significantly to Hispanic male (lung and bronchus, colon and rectum, liver, prostate, and pancreas cancers) and female (lung and bronchus, liver, pancreas, colon and rectum, female breast, and ovary cancers) mortality were selected for analysis. 5-year age-adjusted mortality rates [(95% confidence interval); per 100,000] and standardized mortality ratios (95% confidence interval) using foreign-born as the reference group were calculated. Joinpoint regression analysis was used to model cancer-related mortality trends. Results: Puerto Rico–born Puerto Ricans, Cuba-born Cubans, and US-born Mexicans had some of the highest cancer death rates among all the Hispanic groups. In general, foreign-born Hispanics had higher cancer mortality rates than US-born Hispanics, except Mexicans. Overall, US-born and non–US-born (i.e., native- or foreign-born) Hispanic groups experienced decreasing rates of cancer deaths over the years. Conclusions: We noted vast heterogeneity in mortality rates by nativity across Hispanic groups, a fast-growing diverse US population. Impact: Understanding disaggregated patterns and trends in cancer burden can motivate deeper discussion around community health resources, which may improve the health of Hispanics across the United States.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (12)

Patricia D. Jones

University of Miami Miller School of Medicine

UNITED STATES
View details

Robert J. Wong

Stanford University School of Medicine

UNITED STATES
View details

Amit G. Singal

-

UNITED STATES
View details

Isildinha Reis

Research Professor

University of Miami Health System

UNITED STATES
View details

Wei Zhang

Transplant hepatologist/Assistant professor

Massachusetts General Hospital

UNITED STATES
View details

Caroline Thompson

Associate Professor

University of North Carolina at Chapel Hill Gillings School of Global Public Health

UNITED STATES
View details

Erin N. Kobetz

University of Miami Miller School of Medicine

UNITED STATES
View details

Mandana Khalili

Professor of Medicine

University of California, San Francisco

UNITED STATES
View details

Latha Palaniappan

Stanford University

UNITED STATES
View details

Heidy N. Medina

University of Miami

UNITED STATES
View details

Gilberto Lopes

Associate Professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Malathi Srinivasan

Clinical Professor of Medicine

Stanford University School of Medicine

UNITED STATES
View details